Leprosy: Review of the epidemiological, clinical, and etiopathogenic aspects - Part 1

Anais Brasileiros de Dermatologia

Volumn 89, Issue 2, 2014, Pages 205-218

  Lastória, Joel Carlos ^a   de Abreu, Marilda Aparecida Milanez Morgado ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSIDADE DO OESTE PAULISTA UNOESTE   (Brazil)

Author keywords

Classification; Clinical diagnosis; Continuing; Disease transmission; Education; Epidemiology; Genetic phenomena; Immunologic factors; Infectious; Leprosy; Mycobacterium leprae; Signs and symptoms

Indexed keywords

ARTICLE; DELAYED HYPERSENSITIVITY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE CONTROL; ELECTRON MICROSCOPY; FACIAL NERVE DISEASE; GENETIC POLYMORPHISM; HEREDITY; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; LEPROSY; MYCOBACTERIUM LEPRAE; NERVE LESION; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREVALENCE; SYSTEMIC DISEASE;

BRAZIL; FEMALE; HUMANS; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; SKIN DISEASES, BACTERIAL;

EID: 84899408926     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20142450     Document Type: Article

References (116)

1. Eidt LM. Breve história da hanseníase: sua expansão do mundo para as Américas, o Brasil e o Rio Grande do Sul e sua trajetória na saúde pública brasileira. Saúde Soc. 2004;13:76-88.
2. Cavaliere IAL, Costa SG. Isolamento social, sociabilidades e redes sociais de cuidados. Physis. 2011;21:491-516.
3. Cunha VS. Solated 'like us' or isolated 'among us'?: the controversy within the National Academy of Medicine over compulsory isolation of leprosy sufferers. Hist Cienc Saude Manguinhos. 2010;17:939-954.
4. Opromolla PA, Martelli ACC. Terminology related to Hansen's disease. An Bras Dermatol. 2005;80:293-4.
5. Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012;87:317-28.
6. Paho. org [homepage on the internet]. World Health Organization. Elimination of leprosy as a public health problem. Leprosy Resolution WHA 44.9, 44th World Health Assembly. Geneva; 1991. [cited 2012 oct 19]. Availabre from: http://www.paho.org/English/AD/DPC/CD/lep-wha-1991.htm.
7. Saude. gov. br [homepage on the Internet]. Distribuição da hanseníase no Brasil. [acesso 19 out 2012]. Disponível em: http://portal.saude.gov.br/portal/saude/profissional/ visualizar_texto.cfm?idtxt=31200.
8. o 3.125, de 07 de outubro de 2010. Aprova as Diretrizes para Vigilância, Atenção e Controle da hanseníase. [acesso 19 out 2012]. Disponível em: http://portal.saude.gov.br/portal/arquivos/pdf/portaria_ n_3125_hanseniase_2010.pdf
9. Talhari S, Grossi MA, Oliveira ML, Gontijo B, Talhari C, Penna GO. Hansen's disease: a vanishing disease? Mem Inst Oswaldo Cruz. 2012;107:13-6.
10. Penna MLF, Oliveira MLW, Carmo EH, Penna GO, Temporão JG. The influence of increased access to basic healthcare on the trends in Hansen's disease detection rate in Brazil from 1980 to 2006. Rev Soc Bras Med Trop. 2008;41:6-10.
11. Barbieri CL, Marques HH. Leprosy in children and adolescents: bibliographical review and current situation in Brazil. Pediatria (São Paulo). 2009;31:281-90.
12. Ignotti E, Rodrigues AM, Andrade VLG, Valente JG. Aplicação de métodos de estimativa da prevalência de hanseníase no Estado de Mato Grosso. Rev Bras Epidemiol. 2004;7:155-66.
13. Goulart IB, Dias CM, Oliveira ACS, Silva AA, Alves RR, Quaresmin CR et al. Grau de incapacidade: indicador de prevalência oculta e qualidade do programa de controle da hanseníase em um centro de saúde-escola no município de Uberlândia-MG. Hansen int. 2002;27:5-13.
14. da Cunha MD, Cavaliere FA, Hércules FM, Duraes SM, de Oliveira ML, de Matos HJ. Os indicadores da hanseníase e as estratégias de eliminação da doença, em município endêmico do Estado do Rio de Janeiro, Brasil. Cad Saude Publica. 2007;23:1187-97.
15. Rees RJW, Young DB. The microbiology of leprosy. In: Hastings RC, editor. Leprosy. 2nd ed. New York: Churchill Livingstone; 1994. p.49-83.
16. Nolte FS, Metchok B. Mycobacterium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 6th ed. Washington: American Society for Microbiology; 1995. p. 400-37.
17. Shepard CC. Temperature optimum of Mycobacterium leprae in mice. J Bacteriol. 1965;90:1271-5.
18. Hastings RC, Brand PW, Mansfield RE, Ebner JD. Bacterial density in the skin in lepromatous leprosy as related to temperature. Lepr Rev. 1968;39(2):71-4.
19. Desikan KV. Viability of Mycobacterium leprae outside the human body. Lepr Rev. 1977;48:231-5.
20. Draper P. The bacteriology of Mycobacterium leprae. Tubercle. 1983;64:43-56.
21. Hirata T. Electron microscopic observations of cell wall and cytoplasmic membrane in murine and human leprosy bacilli. Int J Lepr Other Mycobact Dis. 1985;53:433-40.
22. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature. 2001;409:1007-11.
23. Vissa VD, Brennan PJ. The genome of Mycobacterium leprae: a minimal mycobacterial gene set. Genome Biol. 2001;2:REVIEWS1023.
24. Deps PD, Antunes JM, Tomimori-Yamashita J. Detection of Mycobacterium leprae infection in wild nine-banded armadillos (Dasypus novemcinctus) using the rapid ML Flow test. Rev Soc Bras Med Trop. 2007;40:86-7.
25. Donham KJ, Leininger JR. Spontaneous leprosy-like disease in a chimpanzee. J Infect Dis. 1977;136:132-6.
26. Walsh GP, Meyers WM, Binford CH, Gerone PJ, Wolf RH, Leininger JR. Leprosy--a zoonosis. Lepr Rev. 1981;52:77-83.
27. Kazda J, Ganapati R, Revankar C, Buchanan TM, Young DB, Irgens LM. Isolation of environment-derived Mycobacterium leprae from soil in Bombay. Lepr Rev. 1986;57:201-8.
28. Matsuoka M, Izumi S, Budiawan T, Nakata N, Saeki K. Mycobacterium leprae DNA in daily using water as a possible source of leprosy infection. Indian J Lepr. 1999;71:61-7.
29. Bona SH, Fonseca APM, Silva ACL, Costa RJ. Bacilos álcool-ácido resistentes no Culex fatigans. An Bras Dermatol. 1985;60:163-70.
30. Shepard CC. The nasal excretion of Mycobacterium leprae in leprosy. Int J Lepr. 1962;30:10-8.
31. Martins AC, Miranda A, Oliveira ML, Bührer-Sékula S, Martinez A. Estudo da mucosa nasal de contatos de hanseníase, com positividade para o antígeno glicolipídio fenólico 1. Braz J Otorhinolaryngol. 2010;76:579-87.
32. Job CK. Nasal mucosa and abraded skin are the two routes of entry of Mycobacterium leprae. Star. 1990;49:1.
33. Ghorpade A. Inoculation (tattoo) leprosy: a report of 31 cases. J Eur Acad Dermatol Venereol. 2002;16:494-9.
34. Santos AR, Balassiano V, Oliveira ML, Pereira MA, Santos PB, Degrave WM, et al. Detection of Mycobacterium leprae DNA by polymerase chain reaction in the blood of individuals, eight years after completion of anti-leprosy therapy. Mem Inst Oswaldo Cruz. 2001;96:1129-33.
35. Melsom R, Harboe M, Duncan ME, Bergsvik H. IgA and IgM antibodies against Mycobacterium leprae in cord sera and in patients with leprosy: an indicator of intrauterine infection in leprosy. Scand J Immunol. 1981;14:343-52.
36. Pedley JC. The presence of M. leprae in human milk. Lepr Rev. 1967;38:239-42.
37. Klatser PR, van Beers S, Madjid B, Day R, de Wit MY. Detection of Mycobacterium leprae nasal carriers in populations for which leprosy is endemic. J Clin Microbiol. 1993;31:2947-51.
38. Hatta M, van Beers SM, Madjid B, Djumadi A, de Wit MY, Klatser PR. Distribution and persistence of Mycobacterium leprae nasal carriage among a population in which leprosy is endemic in Indonesia. Trans R Soc Trop Med Hyg. 1995;89:381-5.
39. van Beers SM, de Wit MY, Klatser PR. The epidemiology of Mycobacterium leprae: recent insight. FEMS Microbiol Lett. 1996;136:221-30.
40. Cree IA, Smith WC. Leprosy transmission and mucosal immunity: towards eradication? Lepr Rev. 1998;69:112-21.
41. Pattyn SR, Ursi D, Ieven M, Grillone S, Raes V. Detection of Mycobacterium leprae by the polymerase chain reaction in nasal swabs of leprosy patients and their contacts. Int J Lepr Other Mycobact Dis. 1993;61:389-93.
42. van Beers SM, Izumi S, Madjid B, Maeda Y, Day R, Klatser PR. An epidemiological study of leprosy infection by serology and polymerase chain reaction. Int J Lepr Other Mycobact Dis. 1994;62:1-9.
43. Ramaprasad P, Fernando A, Madhale S, Rao JR, Edward VK, Samson PD, et al. Transmission and protection in leprosy: indications of the role of mucosal immunity. Lepr Rev. 1997;68:301-15.
44. Izumi S, Budiawan T, Saeki K, Matsuoka M, Kawatsu K. An epidemiological study on Mycobacterium leprae infection and prevalence of leprosy in endemic villages by molecular biological technique. Indian J Lepr. 1999;71:37-43.
45. Patrocínio LG, Goulart IM, Goulart LR, Patrocínio JA, Ferreira FR, Fleury RN. Detection of Mycobacterium leprae in nasal mucosa biopsies by the polymerase chain reaction. FEMS Immunol Med Microbiol. 2005;44:311-6.
46. Job CK, Jayakumar J, Kearney M, Gillis TP. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg. 2008;78:518-21.
47. Baumgart KW, Britton WJ, Mullins RJ, Basten A, Barnetson RS. Subclinical infection with Mycobacterium leprae--a problem for leprosy control strategies. Trans R Soc Trop Med Hyg. 1993;87:412-5.
48. Brasil MTLRF, Oliveira LR, Melo CS, Nakamura PM, Rimoli NS, Cavalari FS et al. Aplicação do teste Elisa anti-PGL-1 em localidade com alta edemicidade de hanseníase, na Região Norte do Estado de São Paulo. Hansen Int. 1998;23:35-48.
49. de Wit MY, Douglas JT, McFadden J, Klatser PR. Polymerase chain reaction for detection of Mycobacterium leprae in nasal swab specimens. J Clin Microbiol. 1993;31:502-6.
50. Fine PE, Sterne JA, Pönnighaus JM, Bliss L, Saui J, Chihana A, et al. Household and dwelling contact as risk factors for leprosy in northern Malawi. Am J Epidemiol. 1997;146:91-102.
51. Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev. 2004;75:310-26.
52. Mira MT, Sindeaux RHM, Ramos GB, Sotomaior VS, Medeiros Fava V. Aspectos genéticos da suscetibilidade do hospedeiro à hanseníase. Salud cienc. 2011;18:138-41
53. Prevedello FC, Mira MT. Leprosy: a genetic disease? An Bras Dermatol. 2007;82:451-9.
54. Mira MT, Alcaïs A, Nguyen VT, Moraes MO, Di Flumeri C, Vu HT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature. 2004;427:636-40.
55. Alcaïs A, Alter A, Antoni G, Orlova M, Nguyen VT, Singh M, et al. Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early-onset leprosy. Nat Genet. 2007;39:517-22.
56. Cooke GS, Hill AV. Genetics of susceptibility to human infectious disease. Nat Rev Genet. 2001;2:967-77.
57. Roy S, McGuire W, Mascie-Taylor CG, Saha B, Hazra SK, Hill AV, et al. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis. 1997;176:530-2.
58. Moraes MO, Pacheco AG, Schonkeren JJ, Vanderborght PR, Nery JA, Santos AR, et al. Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun. 2004;5:592-5.
59. Malhotra D, Darvishi K, Sood S, Sharma S, Grover C, Relhan V, et al. IL-10 promoter single nucleotide polymorphisms are significantly associated with resistance to leprosy. Hum Genet. 2005;118:295-300.
60. Santos AR, Suffys PN, Vanderborght PR, Moraes MO, Vieira LM, Cabello PH, et al. Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis. 2002;186:1687-91
61. Shaw MA, Donaldson IJ, Collins A, Peacock CS, Lins-Lainson Z, Shaw JJ, et al. Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes. Genes Immun. 2001;2:196-204.
62. Franceschi DS, Mazini PS, Rudnick CC, Sell AM, Tsuneto LT, Ribas ML, et al. Influence of TNF and IL10 gene polymorphisms in the immunopathogenesis of leprosy in the south of Brazil. Int J Infect Dis. 2009;13:493-8.
63. Sarno EN, Santos AR, Jardim MR, Suffys PN, Almeida AS, Nery JA, et al. Pathogenesis of nerve damage in leprosy: genetic polymorphism regulates the production of TNF? Lepr Rev. 2000;71:S154-8
64. Zhang FR, Huang W, Chen SM, Sun LD, Liu H, Li Y, et al. Genomewide association study of leprosy. N Engl J Med. 2009;361:2609-18.
65. Meisner SJ, Mucklow S, Warner G, Sow SO, Lienhardt C, Hill AV. Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy in west Africans. Am J Trop Med Hyg. 2001;65:733-5.
66. Siddiqui MR, Meisner S, Tosh K, Balakrishnan K, Ghei S, Fisher SE, et al. A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nat Genet. 2001;27:439-41.
67. Roy S, Frodsham A, Saha B, Hazra SK, Mascie-Taylor CG, Hill AV. Association of vitamin D receptor genotype with leprosy type. J Infect Dis. 1999;179:187-91.
68. Bochud PY, Hawn TR, Siddiqui MR, Saunderson P, Britton S, Abraham I, et al. Tolllike receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis. 2008;197:253-61
69. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338-81.
70. Modlin RL, Bloom BR. Immune regulation: learning from leprosy. Hosp Pract (Off Ed). 1993;28:71-4, 77-80, 83-4.
71. Mendonça VA, Costa RD, Melo GEBA, Antunes CM, Teixeira AL. Immunology of leprosy. An Bras Dermatol. 2008;83:343-50.
72. Oliveira MLW, Cavaliére FAM, Maceira JMP, Bührer-Sékula S. The use of serology as an additional tool to support diagnosis of difficult multibacillary leprosy cases: lessons from clinical care. Rev Soc Bras Med Trop. 2008;41:27-33.
73. Ottenhoff TH. Immunology of leprosy: lessons from and for leprosy. Int J Lepr Other Mycobact Dis. 1994;62:108-21.
74. Van Voorhis WC, Kaplan G, Sarno EN, Horwitz MA, Steinman RM, Levis WR, et al. The cutaneous infiltrates of leprosy: cellular characteristics and the predominant Tcell phenotypes. N Engl J Med. 1982;307:1593-7.
75. Modlin RL, Hofman FM, Taylor CR, Rea TH. T lymphocyte subsets in the skin lesions of patients with leprosy. J Am Acad Dermatol. 1983;8:182-9.
76. Narayanan RB, Bhutani LK, Sharma AK, Nath I. T cell subsets in leprosy lesions: in situ characterization using monoclonal antibodies. Clin Exp Immunol. 1983;51:421-9.
77. Modlin RL, Mehra V, Wong L, Fujimiya Y, Chang WC, Horwitz DA, et al. Suppressor T lymphocytes from lepromatous leprosy skin lesions. J Immunol. 1986;137:2831-4.
78. Modlin RL, Melancon-Kaplan J, Young SM, Pirmez C, Kino H, Convit J, et al. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci U S A. 1988;85:1213-7.
79. Sieling PA, Abrams JS, Yamamura M, Salgame P, Bloom BR, Rea TH, et al. Immunosuppressive roles for IL-10 and IL-4 in human infection: In vitro modulation of T cell responses in leprosy. J Immunol. 1993;150:5501-10.
80. Scollard DM. Inside the skin: the local immune and inflammatory milieu in leprosy. Am J Trop Med Hyg. 1991;44:17-23.
81. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1991;254:277-9.
82. Sieling PA, Modlin RL. T cell and cytokine patterns in leprosy skin lesions. Springer Semin Immunopathol. 1992;13:413-26.
83. Silva CL, Foss NT. Tumor necrosis factor in leprosy patients. J Infect Dis. 1989;159:787-90.
84. Warwick-Davies J, Lowrie DB, Cole PJ. Selective deactivation of human monocyte functions by TGF-beta. J Immunol. 1995;155:3186-93.
85. Henao MI, Montes C, París SC, García LF. Cytokine gene polymorphisms in Colombian patients with different clinical presentations of tuberculosis. Tuberculosis (Edinb). 2006;86:11-9.
86. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of Th1 CD4+ T-cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260:547-9.
87. Sieling PA, Modlin RL. Cytokine patterns at the site of mycobacterial infection. Immunobiology. 1994;191:378-87.
88. Yamamura M, Wang XH, Ohmen JD, Uyemura K, Rea TH, Bloom BR, et al. Cytokine patterns of immunologically mediated tissue damage. J Immunol. 1992;149:1470-5.
89. Foss NT. Aspectos imunológicos da hanseníase. Medicina (Ribeirão Preto). 1997;30:335-9.
90. Report of the committee on classification. International Congress of leprosy, Madrid; 1953. Int J Lepr. 1953;21:504-16.
91. Rabello Júnior FE. Uma classificação clínico-epidemiológica das formas de lepra. Rev Bras Leprol. 1936;:375-410.
92. Ridley DS, Jopling WH. A classification of leprosy for research purposes. Lepr Rev. 1962;33:119-28.
93. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A fivegroup system. Int J Lepr Other Mycobact Dis. 1966;34:255-73.
94. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser. 1982;675:1-33.
95. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 1988;768:1-51.
96. Contin LA, Alves CJM, Fogagnolo L, Nassif PW, Barreto JA, Lauris JRPL et al. Use of the ML-Flow test as a tool in classifying and treating leprosy. An Bras Dermatol. 2011;86:91-5.
97. Bührer-Sékula S, Smits HL, Gussenhoven GC, van Leeuwen J, Amador S, Fujiwara T, et al. Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol. 2003;41:1991-5.
98. Nery JAC, Sales AM, Illarramendi X, Duppre NC, Jardim MR, Machado AM. Contribuição ao diagnóstico e manejo dos estados reacionais: Uma abordagem prática. An bras dermatol. 2006;81(4):367-375.
99. Douglas JT, Cellona RV, Fajardo TT Jr, Abalos RM, Balagon MV, Klatser PR. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diagn Lab Immunol. 2004;11:897-900.
100. Noordeen SK. Long term effects of chemoprophylaxis among contacts of lepromatous cases. Results of 8 1/2 years follow-up. Lepr India. 1977;49:504-9.
101. Meneses S, Cirelli NM, Aranzazu N, Rondon Lugo AJ. Lepra visceral: presentacion de dos casos y revision de la literatura. Dermatol Venez. 1988;26:79-84.
102. Kahawita IP, Walker SL, Lockwood DNJ. Leprosy type 1 reactions and erythema nodosum leprosum. An Bras Dermatol. 2008;83:75-82.
103. Monteiro R, Abreu MA, Tiezzi MG, Roncada EV, Oliveira CC, Ortigosa LC. Lucio's phenomenon: another case reported in Brazil. An Bras Dermatol. 2012;87:296-300.
104. Garbino JA. O paciente com suspeita de hanseníase primariamente neural / The patient with suspicion of primarily neural leprosy. Hansen Int. 2007;32:203-6.
105. Martins CF. Exame palpatório de nervos periféricos (espessados na hanseníase) e suas vias anatômicas. An Bras Dermatol. 1995;70:247-50.
106. Agrawal A, Pandit L, Dalal M, Shetty JP. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg. 2005;107:445-54.
107. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Caderno de prevenção e reabilitação em hanseníase. 3. ed., rev. e ampl Brasília: Ministério da Saúde; 2008. 140 p. (Série A. Normas e Manuais Técnicos) (Cadernos de prevenção e reabilitação em hanseníase; n. 1).
108. Lehman LF, Orsini MBP, Fuzikawa PL, Lima RC, Gonçalves SD. Avaliação neurológica simplificada. Belo Horizonte: ALM internacional, 1997. 104 p.
109. Gopinath DV, Thappa DM, Jaishankar TJ. A clinical study of the involvement of cranial nerves in leprosy. Indian J Lepr. 2004;76:1-9.
110. Lewallen S, Tungpakorn NC, Kim SH, Courtright P. Progression of eye disease in "cured" leprosy patients: implications for understanding the pathophysiology of ocular disease and for addressing eyecare needs. Br J Ophthalmol. 2000;84:817-21.
111. Mattar Jr R, Azze RJ. Lesão dos nervos periféricos. In: Mattar Júnior R, Azzer RJ. Atualização em traumatologia do aparelho locomotor. [acesso 19 out 2012]. Disponível em: http://www.ronaldoazze.com.br/fasciculo/fasciculo3.PDF
112. Klioze AM, Ramos-Caro FA. Visceral leprosy. Int J Dermatol. 2000;39:641-58.
113. de Abreu MA, Michalany NS, Weckx LL, Neto Pimentel DR, Hirata CH, de Avelar Alchorne MM. The oral mucosa in leprosy: a clinical and histopathological study. Braz J Otorhinolaryngol. 2006;72:312-6.
114. Morgado de Abreu MA, Neto Pimentel DR, Morgado de Abreu NM, Watashi Hirata CH, Michalany NS, Maurice Weckx LL, et al. Presence of oral lesions in leprosy patients does not imply involvement by Mycobacterium leprae. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:328-9.
115. de Abreu MA, Alchorne MM, Michalany NS, Weckx LL, Pimentel DR, Hirata CH. The oral mucosa in paucibacillary leprosy: a clinical and histopathological study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:e48-52.
116. Leal AMO. Endocrine changes in leprosy. Medicina (Ribeirão Preto). 1997; 340-4.